Merus N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRUS research report →
Range $30 – $99
Price Chart
About the company
Merus N. V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies.
- CEO
- Jan van de Winkel
- IPO
- 2016
- Employees
- 260
- HQ
- Utrecht, NL
Get TickerSpark's AI analysis on MRUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.83B
- P/E
- -25.79
- Fwd P/E
- 516.38
- PEG
- 0.63
- P/S
- 347.46
- P/B
- 10.29
- EV/EBITDA
- -38.55
- Div Yield
- 0.00%
- Gross Margin
- -309.19%
- Op Margin
- -968.01%
- Net Margin
- -1170.00%
- ROE
- -30.58%
- ROIC
- -27.16%
Latest fiscal year · YoY change
- Revenue
- $34.88M-12.4%
- Gross Profit
- $12.96M-55.8%
- Op Income
- $-262,626,275
- Net Income
- $-207,854,187-48.1%
- EPS
- $-3.35-11.7%
- OCF Growth
- -30.7%
- FCF Growth
- -28.3%
- 52W High
- $97.14
- 52W Low
- $33.19
- 50D MA
- $95.61
- 200D MA
- $68.01
- Beta
- 1.06
- RSI (14)
- 15
- Avg Volume
- 1.72M
No earnings-call transcripts are available for MRUS yet.
- Free Float
- 92.3%
- Shares Outstanding
- 75.84M
- Float Shares
- 70.01M
of shares held by institutions
294 13F filers
Buy/sell ratio 0.21. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Axa Investment Managers S.A. | 52.61K | ▲ 52.61K |
| Nuveen Asset Management, LLC | 36.42K | ▼ 975 |
| Glenmede Investment Management, LP | 9.54K | ▼ 1.98K |
| Allostery Investments LP | 9.00K | ▼ 115.66K |
| Corton Capital Inc. | 2.24K | ▲ 2.24K |
| Point72 Europe (London) Llp | 1.16K | ▲ 1.16K |
| Lindbrook Capital, LLC | 76 | 0 |
Held by 5 ETFs
Biggest fund positions in MRUS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 29, 25 | GENMAB A/S | buy | 1,052,806 |
| Dec 26, 25 | GENMAB A/S | buy | 2,978 |
| Dec 29, 25 | GENMAB A/S | buy | 75,867,199 |
| Dec 26, 25 | GENMAB A/S | buy | 142,610 |
| Dec 24, 25 | GENMAB A/S | buy | 96,082 |
| Dec 23, 25 | GENMAB A/S | buy | 561,042 |
| Dec 22, 25 | GENMAB A/S | buy | 15,710 |
| Dec 19, 25 | GENMAB A/S | buy | 66,264 |
| Dec 18, 25 | GENMAB A/S | buy | 212,177 |
| Dec 17, 25 | GENMAB A/S | buy | 150,795 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MRUS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MRUS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 7
Merus Power Delivers an Energy Storage System for Extreme Arctic Conditions
businesswire.com · Feb 11
Federated Hermes Inc. Sells 279,425 Shares of Merus N.V. $MRUS
defenseworld.net · Jan 29
Merus N.V. (NASDAQ:MRUS) Receives Average Recommendation of “Hold” from Analysts
defenseworld.net · Jan 7
Market Today: Tesla dethroned; Wall St. starts 2026 higher
gurufocus.com · Jan 2
First Look: Futures Climb, FTSE 10,000, BYD Tops Tesla
gurufocus.com · Jan 2
First Look: 2026 Outlook, Buffett Exit, Fed Split, Dollar Slide
gurufocus.com · Jan 1
A/S Genmab Buys 2,978 Shares of Merus (NASDAQ:MRUS) Stock
defenseworld.net · Jan 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.